08/24/2006

Leading Drug Researcher to Visit WVU

Robert R. Ruffolo, Jr., Ph.D., leads R & D at Wyeth

MORGANTOWN, W.Va. – Robert R. Ruffolo, Jr., Ph.D., president, research and development at Wyeth Pharmaceuticals, will speak with West Virginia University Health Sciences students and faculty at 5 p.m., Thursday, Aug. 31, in the HSC Auditorium at the WVU Health Sciences Center.

His presentation, “Discovery and Development of Coreg to Treat Congestive Heart Failure: The Saga of Carvedilol,” is part of the Robert C. Byrd Health Sciences Center’s Grand Rounds series and is free and open to the public.

Ruffolo is also senior vice president of Wyeth, a research-based, global pharmaceutical company responsible for the discovery and development of some of today’s most innovative medicines.

One year ago, Ruffolo announced a joint research partnership between WVU HSC and Wyeth Pharmaceuticals. Wyeth will invest nearly $12 million in biosciences research at the University to support up to 15 new faculty positions.

“The Wyeth Research Fund has added strength to our research programs, and has deepened our teaching faculty and clinical departments,” said Robert M. D’Alessandri, M.D., WVU vice president for health sciences. “Their support has enhanced our research in three of our six core research areas – cardiovascular sciences, respiratory biology and diabetes/obesity.”                       

Dr. Ruffolo received his B.S. from Ohio State University, graduating summa cum laude and with Distinction in Pharmacy. He then received his Ph.D. in Pharmacology at Ohio State before beginning his career as a fellow at the National Institutes of Health. He spent six years at Eli Lilly & Co., then 17 years at SmithKline Beecham in various research positions.

He joined Wyeth in 2000 and became head of Research and Development in 2002.

Dr. Ruffolo has played a significant role in the discovery and development of several marketed products, including Dobutamine for congestive heart failure, Ropinerole for Parkinson’s Disease, Eprosartan for hypertension and Carvedilol for hypertension, angina, myocardial infarction and congestive heart failure.

Ruffolo was named one of two Chief Scientific Officers of the Year in the 2004 Pharmaceutical Achievement Awards. He has authored nearly 500 full-length publications and 200 abstracts and has edited 17 books.

He was also identified by The American Society for Information Science & Technology as a Highly Cited Scientist for being among the top 100 cited pharmacologists in the world over the past two decades.           

 

- WVU -


06-184
For more information:
Steve Bovino, HSC News Service, (304) 293-7087
bovinost@wvuh.com
sfb:08-23-06

Return To News Releases